Tenofovir alafenamide

Drug Profile

Tenofovir alafenamide

Alternative Names: GS-7340; GS-7340-02; GS-7340-03; TAF; Tenofovir alafenamide fumarate; Vemlidy

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antiretrovirals; Purines; Small molecules
  • Mechanism of Action Nucleotide reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Hepatitis B
  • Phase III HIV-1 infections

Most Recent Events

  • 12 Jun 2017 Gilead Sciences plans a phase II trial for Hepatitis B (NCT03180619)
  • 20 Apr 2017 Efficacy data from two phase III trials in Hepatitis B released by Gilead
  • 18 Apr 2017 University Hospital Inselspital plans a phase II trial for HIV infection and Hepatitis B (NCT03115736)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top